

## Epidemiological Surveillance of Respiratory Infections Weekly overview Week 30/2023 (24/7/2023 – 30/7/2023)

Influenza-like Illness (ILI)

• ILI rate remained low

## SARS-CoV2 virus - COVID-19 infection

- test positivity showed an increase compared to the previous week
- the number of COVID-19 admissions (n=321) increased compared to the previous week and a 41% increase compared to the average weekly number of new admissions during the previous 4 weeks
- the number of new intubations (n=9) increased compared to the previous week and a 125% increase compared to the average weekly number of new admissions during the previous 4 weeks
- the cumulative number of intubated patients with COVID-19 infection is 16
- 24 deaths were reported (median age: 87,5 years, range: 67-97)
- during the last weeks all sequenced samples were classified as Omicron sub-variants BA.2 and BA.5, with BA.2 being the dominant variant from week 9 onwards
- in week 25 the most frequent BA.2 sub-variants were XBB.1.5 (80%) followed by XBB.1.16 (18%)
- viral load surveillance in municipal wastewater showed an increase in SARS-CoV-2
   virus circulation in 8 out of 10 areas participating in the network

## Influenza virus

- the percentage of sentinel primary care specimens from patients presenting with ILI that tested positive for an influenza virus remains below 10% (sentinel)
- no severe cases of laboratory-confirmed influenza admitted to ICU or deaths from laboratory-confirmed influenza were recorded in week 30/2023
- from week 40/2022 to week 30/2023, 68 cases were hospitalized in ICU and 26 deaths were reported
- during the same period, 375 samples positive for influenza viruses (sentinel samples and hospital samples) were detected in the two Influenza Reference Centers, of which 290 (77,3%) were type A and 85 (22,7%) were type B
- of the 288 type A viruses subtyped, 258 (90%) were classified as subtype A(H3N2) and 30 (10%) as subtype A(H1N1)pdm09

Respiratory syncytial virus – RSV

all samples were tested negative for RSV